Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Clinical Trial

Official title:
A Phase Ib,Open Label,Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Status Recruiting

Clinical Trial Summary

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Clinical Trial Description

The objective of the trial is to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (afatinib or osimertinib) in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study, and Stage II was a dose expansion study. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung Neoplasms

Clinical Trial Details

NCT number	NCT04448379
Study type	Interventional
Source	Shanghai JMT-Bio Inc.
Contact	Xiugao Yang
Phone	8021-60677906
Email	yangxiugao@mail.ecspc.com
Status	Recruiting
Phase	Phase 1
Start date	June 29, 2020
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05513664` - Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
Recruiting	`NCT05048797` - A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Phase 3
Not yet recruiting	`NCT05132777` - Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04606446` - Study of PF-07248144 in Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05673590` - Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04686305` - Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	Phase 1
Recruiting	`NCT05863325` - A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2
Recruiting	`NCT04996121` - A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2